Evidence map›Paper›PMID 25153931›Full record

ArticlePloS one2014

Prioritizing candidate disease metabolites based on global functional relationships between metabolites in the context of metabolic pathways.

Desi Shang, Chunquan Li, Qianlan Yao, Haixiu Yang, Yanjun Xu, Junwei Han, Jing Li, Fei Su, Yunpeng Zhang, Chunlong Zhang and 2 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Desi ShangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Chunquan LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China; School of Medical Informatics, Daqing Campus, Harbin Medical University, Daqing, P. R. China.
Qianlan YaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Haixiu YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Yanjun XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Junwei HanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Jing LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Fei SuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Yunpeng ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Chunlong ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
Dongguo LiSchool of Biomedical Engineering, Capital Medical University, No. 10 You An Men Wai Xi Tou Tiao, Beijing, P.R. China.
Xia LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of key metabolites for complex diseases is a challenging task in today's medicine and biology. A special disease is usually caused by the alteration of a series of functional related metabolites having a global influence on the metabolic network. Moreover, the metabolites in the same metabolic pathway are often associated with the same or similar disease. Based on these functional relationships between metabolites in the context of metabolic pathways, we here presented a pathway-based random walk method called PROFANCY for prioritization of candidate disease metabolites. Our strategy not only takes advantage of the global functional relationships between metabolites but also sufficiently exploits the functionally modular nature of metabolic networks. Our approach proved successful in prioritizing known metabolites for 71 diseases with an AUC value of 0.895. We also assessed the performance of PROFANCY on 16 disease classes and found that 4 classes achieved an AUC value over 0.95. To investigate the robustness of the PROFANCY, we repeated all the analyses in two metabolic networks and obtained similar results. Then we applied our approach to Alzheimer's disease (AD) and found that a top ranked candidate was potentially related to AD but had not been reported previously. Furthermore, our method was applicable to prioritize the metabolites from metabolomic profiles of prostate cancer. The PROFANCY could identify prostate cancer related-metabolites that are supported by literatures but not considered to be significantly differential by traditional differential analysis. We also developed a freely accessible web-based and R-based tool at http://bioinfo.hrbmu.edu.cn/PROFANCY.

Indexed as

Metabolic Networks and PathwaysSoftwareAlgorithmsAlzheimer DiseaseComputer SimulationHumansMaleMetabolomicsProstatic NeoplasmsProtein Interaction Mapping

Identifiers

PMID25153931
PMCPMC4143229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.